India Pharma Outlook Team | Tuesday, 30 September 2025
Welcure Drugs & Pharmaceuticals stated on Monday that its board has analyzed and approved a proposal from Singapore's Telexcell Trade Pte to obtain as much as 25% of the company.
The board noted that Telexcell will be considered solely as a financial investor and will not have rights of management or control of the company.
Welcure announced that Telexcell is proposing to acquire the interest at ?20 per share and that the offer signifies Telexcell's strong confidence in the company's inherent value. The board noted that Telexcell made a qualified approach to influence management and decision-making of the company, which was unanimously rejected.
Also Read: Role of Optical Imaging in Early Cancer Detection and Treatment
Furthermore, Welcure emphasized any share acquisition by Telexcell will occur only through secondary market acquisitions, such as bulk deals, to ensure no liability on the company and no dilutive value to current shareholders.
Simultaneously, however, Welcure acknowledged Telexcell's desire for strategic positioning and that it is quite a premium valuation. The board resolved that if a fund raise occurs in the future, Telexcell will be arranged as a first priority as a partner, subject to required regulatory approvals. Welcure qualified its statement by announcing it does not plan to raise any fresh capital at this time.
The development marks a significant industry move, as Welcure Drugs positions itself to attract global interest while firmly protecting shareholder value and retaining full management independence.
